Andrew Gu was appointed as Class III Director at Cellectar Biosciences, Inc..
“On May 18, 2026, the Board appointed Mr. Gu to serve as a member of the Board as a Class III director.”
Cellectar Biosciences, Inc. — fact timeline
Source-grounded facts extracted from Cellectar Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Stefan D. Loren departed as Class III Director at Cellectar Biosciences, Inc..
“On May 17, 2026, Stefan D. Loren, Ph.D. notified the board of directors (the “Board”) of Cellectar Biosciences, Inc. (the “Company”), that he does not intend to stand for reelection as a Class III director at the upcoming 2026 annual meeting of the stockholders of the Company (the “Annual Meeting”), at which time his current term as a director will expire.”
Cellectar Biosciences, Inc. reported financial results for the quarter ended March 31, 2026.
“On May 14, 2026, we issued a press release announcing our financial results for the quarter ended March 31, 2026, and provided a corporate update.”
Cellectar Biosciences, Inc. entered into Registration Rights Agreement with certain investors (effective 2026-05-04).
“on May 4, 2026, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with certain investors”
Cellectar Biosciences, Inc. entered into Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. (effective 2026-05-04).
“on May 4, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Placement Agent”)”
Cellectar Biosciences, Inc. entered into Management Purchase Agreement with certain members of the executive management team of the Company (effective 2026-05-04).
“pursuant to an additional securities purchase agreement with certain members of the executive management team of the Company (the “Management Purchase Agreement””
Cellectar Biosciences, Inc. entered into Investor Purchase Agreement with certain institutional investors (effective 2026-05-04).
“On May 4, 2026, Cellectar Biosciences, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement with certain institutional investors (the “Investor Purchaser Agreement”)”
Cellectar Biosciences, Inc. reported the year ended December 31, 2025 results: net income $21.8 million, EPS $8.35 per basic and diluted share.
“Net loss for the full year ending December 31, 2025, was $21.8 million or $8.35 per basic and diluted share”
Cellectar Biosciences, Inc.: Effected a one-for-thirty reverse stock split by amending the Second Amended and Restated Certificate of Incorporation (effective 2025-06-24).
“On June 24, 2025, Cellectar Biosciences, Inc., a Delaware corporation (the “Company”), effected a one-for-thirty reverse stock split of the Company’s common stock, par value $0.00001 (the “Reverse Split”) by amending its Second Amended and Restated Certificate of Incorporation (the “Amendment”).”
Cellectar Biosciences, Inc.: Amended and restated by-laws to align with Delaware law, revise director nomination procedures, and change quorum requirement from majority to one-third of shares (effective 2025-03-11).
“On March 11, 2025, the Board adopted the Amended and Restated By-Laws of the Company (the " By-Laws "), effective immediately.”
Cellectar Biosciences, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).
“January 30, 2025, Cellectar Biosciences, Inc. (the “Company”) received notice from Nasdaq which indicated that under Nasdaq Listing Rule 5550(a)(2), the Company is required to maintain a minimum bid price for its common stock of $1.00 for continued listing. The notice does not have any immediate impact on the listing of the Company’s stock on the Nasdaq exchange. The Company’s common stock remains listed on the Nasdaq Capital Market. In accordance with the Nasdaq Listing Rules, the Company has 180 calendar days, or until July 29, 2025, to regain compliance with the bid price requirement. In th”
Cellectar Biosciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“January 30, 2025, Cellectar Biosciences, Inc. (the “Company”) received notice from Nasdaq which indicated that under Nasdaq Listing Rule 5550(a)(2), the Company is required to maintain a minimum bid price for its common”
Cellectar Biosciences, Inc. announced a restructuring with charges of approximately $1.7 million affecting overall workforce (approximately 60%).
“will decrease its annual operating costs by approximately $7.5 million. Additionally, the Company estimates that it will incur aggregate severance costs of approximately $1.7 million, which will be recorded primarily in the fourth quarter of 2024 and first quarter of 2025. The cost that the Company expects to incur in connection with the workforce reduction”
Cellectar Biosciences, Inc. reported the quarter ended March 31, 2024 results: net income The net loss attributable to common stockholders for the three months ended March 31, 2024, was ($21.6) million, or $(0., EPS $(0.74) per share.
“Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update”
Cellectar Biosciences, Inc. reported financial results for year ended December 31, 2023.
“Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.”
Cellectar Biosciences, Inc. reported preliminary financial results for three months ended September 30, 2023.
“On November 2, 2023, we issued a press release announcing preliminary financial results for the three months ended September 30, 2023.”
Cellectar Biosciences, Inc.: Increased authorized common stock from 160,000,000 to 170,000,000 shares (effective 2023-10-25).
“On October 25, 2023, Cellectar Biosciences, Inc. (the “Company”) filed a Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of the Company (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to increase the total number of authorized shares of the Company’s common stock from 160,000,000 to 170,000,000.”
Cellectar Biosciences, Inc. shareholders approved Adjournment Proposal – adjournment of the Special Meeting to solicit additional proxies if necessary at the 2023-10-25 meeting.
“(3) approved the adjournment of the Special Meeting, if necessary in the reasonable discretion of the Company’s Board, the Chairman of the Board, the President or the Corporate Secretary to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve any of the other proposals (the “Adjournment Proposal”)”
Cellectar Biosciences, Inc. shareholders approved Amendment Proposal – amendment to increase authorized common stock from 160,000,000 to 170,000,000 shares at the 2023-10-25 meeting.
“(2) approved the amendment of the Company’s Second Amended and Restated Certificate of Incorporation, as amended, to increase the authorized common stock from 160,000,000 to 170,000,000 shares (the “Amendment Proposal”)”
Cellectar Biosciences, Inc. shareholders approved Issuance Proposal – approval of issuance in excess of 19.99% of outstanding common stock upon conversion of Series E Preferred Stock at the 2023-10-25 meeting.
“(1) approved the issuance in excess of 19.99% of the Company’s outstanding common stock upon conversion of the Series E Preferred Stock at less than the “minimum price” and which may be deemed a “change of control” under Nasdaq Listing Rule 5635 (the “Issuance Proposal”)”
Cellectar Biosciences, Inc.: Filed Certificate of Designation designating 1,225 shares of Series E-1, 1,225 shares of Series E-2, 2,205 shares of Series E-3, and 1,715 shares of Series E-4 Convertible Voting Preferred Stock, each with a stated value of $20,000 per share, setting forth rights, preferences and limitations (effective 2023-09-07).
“On September 7, 2023, the Company filed the Certificate of Designation with the Delaware Secretary of State designating 1,225 shares of its authorized and unissued preferred stock as Series E-1 Convertible Voting Preferred Stock, 1,225 shares as Series E-2 Convertible Voting Preferred Stock, 2,205 shares as Series E-3 Convertible Voting Preferred Stock and 1,715 shares as Series E-4 Convertible Voting Preferred Stock (all such series of preferred stock referred to herein collectively as “ Series E Preferred Stock ”), each with a stated value of $20,000 per share (the “ Original Per Share Price ”).”
Cellectar Biosciences, Inc.: Filed Amendment No. 1 to Certificate of Designation of Series D Preferred Stock decreasing authorized shares from 1,519 to 111.1111 (effective 2023-09-07).
“On September 7, 2023, the Company filed with the Delaware Secretary of State an Amendment No. 1 to Certificate of Designation of the Series D Preferred Stock, which, effective upon filing, decreased the authorized number of shares of Series D Preferred Stock from 1,519 to 111.1111 (the “ Amendment No. 1 to Certificate of Designation of the Series D Preferred Stock ”).”
Cellectar Biosciences, Inc.: Filed Certificate of Elimination eliminating all matters set forth in the Certificates of Designations for Series A, Series B, and Series C Convertible Preferred Stock (effective 2023-09-07).
“On September 7, 2023, the Company filed with the Delaware Secretary of State a Certificate of Elimination to the Certificate of Incorporation of the Company which, effective upon filing, eliminated all matters set forth in the applicable Certificates of Designations with respect to the Company’s Series A Convertible Preferred Stock, the Company’s Series B Convertible Preferred Stock and the Company’s Series C Convertible Preferred Stock (the “ Certificate of Elimination ”).”
Cellectar Biosciences, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $24,500,000 (effective 2023-09-05).
“On September 5, 2023, Cellectar Biosciences, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), (i) 1,225 shares of Series E-1 Convertible Voting Preferred Stock, par value $0.0001 per share (the “ Series E-1 Preferred Stock ”), (ii) Tranche A Warrants (the “ Tranche A Warrants ”) to acquire shares of Series E-3 Convertible Voting Preferred Stock, par value $0.00001 per share (the “ Series E-3 Preferred Stock ”) and (iii) Tranche B Warrants (the “ Tranche B Warrants ,” together with the Tranche A Warrants, the “ Warrants ”) to acquire shares of Series E-4 Convertible Voting Preferred Stock, par value $0.00001 per share (the “ Series E-4 Preferred Stock ” and together with the Series E-3 Preferred Stock, the “ Warrant Shares ”) for an aggregate offering price of $24.5 million.”
Cellectar Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“August 16, 2023, Cellectar Biosciences, Inc. (the “Company”) received notice from Nasdaq which indicated that under Nasdaq Listing Rule 5550(b)(1), the Company is required to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. In the Company’s Form 10-Q for the period ended June 30, 2023, the Company reported stockholders’ equity was $(467,004). The notice does not have any immediate impact on the listing of the Company’s stock on Nasdaq. In accordance with the Nasdaq Listing Rules, the Company has 45 calendar days, or until September 30, 2023, to submit a plan to r”
Cellectar Biosciences, Inc. reported the second quarter ended June 30, 2023 results: net income ($8.2) million, or ($0.73) per share, EPS ($0.73) per share.
“The net loss attributable to common stockholders for the three months ended June 30, 2023 was ($8.2) million, or ($0.73) per share, compared to ($7.4) million, or ($1.22) per share, for the three months ended June 30, 2022.”
Cellectar Biosciences, Inc. shareholders approved Approval of Executive Compensation at the 2023-06-23 meeting.
“Proposal No. 4 – Approval of Executive Compensation The Company requested approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. The stockholders approved the compensation of the named executive officers. The vote was as follows: For Against Abstain Broker Non-Votes 3,100,012 311,122 46,985 1,929,917”
Cellectar Biosciences, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-23 meeting.
“Proposal No. 3 – Ratification of Appointment of Independent Registered Public Accounting Firm The Company requested ratification of the appointment by the Audit Committee of the Board of Directors of Baker Tilly US, LLP to be the Company’s independent registered public accounting firm for fiscal year 2023. The stockholders ratified the appointment. The vote was as follows: For Against Abstain 5,283,070 54,947 50,019”
Cellectar Biosciences, Inc. shareholders approved Approval of an Increase in Shares Available under the 2021 Stock Incentive Plan by 1,100,000 Shares at the 2023-06-23 meeting.
“Proposal No. 2 – Approval of an Increase in Shares Available under the 2021 Stock Incentive Plan by 1,100,000 Shares The Company requested approval of an increase in the number of shares of common stock available for issuance under the 2021 Stock Incentive Plan by 1,100,000 shares. The stockholders approved the increase . The vote was as follows: For Against Abstain Broker Non-Votes 3,025,557 389,584 42,978 1,929,917”
Cellectar Biosciences, Inc. shareholders approved Election of Class III Directors at the 2023-06-23 meeting.
“Proposal No.1 – Election of Directors Class III directors, Stefan D. Loren, Ph.D. and Douglas J. Swirsky, were nominated and elected to serve three-year terms. The vote was as follows: Nominee For Withheld Broker Non-Votes Stefan D. Loren, Ph.D. 3,046,236 411,883 1,929,917 Douglas J. Swirsky 3,298,548 159,571 1,929,917”
Cellectar Biosciences, Inc. reported three months ended March 31, 2023 results: net income ($8.6) million, EPS ($0.76) per share.
“The net loss attributable to common stockholders for the three months ended March 31, 2023 was ($8.6) million, or ($0.76) per share”
Cellectar Biosciences, Inc. amended lease obligation of approximately $918,000 with CAMPUS 100 LLC maturing April 30, 2029.
“ntered into an Amended Agreement of Lease (the “Amended Lease”), with CAMPUS 100 LLC (the “Landlord”). Under the Amended Lease, the Company will continue to lease”
Cellectar Biosciences, Inc. amended Amended Agreement of Lease with CAMPUS 100 LLC (the "Landlord") valued at approximately $918,000 (effective 2022-12-30).
“On December 30, 2022, Cellectar Biosciences, Inc. (the “Company”) entered into an Amended Agreement of Lease (the “Amended Lease”), with CAMPUS 100 LLC (the “Landlord”).”
Cellectar Biosciences, Inc.: Amended and restated by-laws to reflect name change, enhance stockholder meeting mechanics, add director nomination requirements, clarify board procedures, and make other updates (effective 2022-11-29).
“On November 29, 2022, the board of directors (the “ Board ”) of the Company adopted the Amended and Restated By-Laws of the Company (the “ By-Laws ”), effective immediately.”
Cellectar Biosciences, Inc. reported nine months ended September 30, 2022 results: net income ($21.4) million, EPS ($3.50) per share.
“the loss attributable to common stockholders for the nine months ended September 30, 2022 was ($21.4) million, or ($3.50) per share, compared to ($18.2) million, or ($3.39) per share, in 2021”
Cellectar Biosciences, Inc. reported third quarter ended September 30, 2022 results: net income ($7.8) million, EPS ($1.28) per share.
“The net loss attributable to common stockholders for the quarter ended September 30, 2022 was ($7.8) million, or ($1.28) per share, compared to ($5.8) million, or ($0.97) per share, in the quarter ended September 30, 2021”
Jarrod Longcor changed role as Chief Operating Officer at Cellectar Biosciences, Inc..
“On February 22, 2022, Jarrod Longcor, age 48, was promoted to the Company’s Chief Operating Officer.”
Chad Kolean was appointed as Chief Financial Officer at Cellectar Biosciences, Inc..
“On February 22, 2022, Chad Kolean, age 57, rejoined the Company as its Chief Financial Officer.”
Dov Elefant resigned as Chief Financial Officer at Cellectar Biosciences, Inc..
“On February 22, 2022, Dov Elefant, the Chief Financial Officer of Cellectar Biosciences, Inc. (the “Company”), resigned from his office effective February 22, 2022.”
Laurence Reilly was appointed as Interim Chief Medical Officer at Cellectar Biosciences, Inc..
“On November 2, 2021, the Company appointed Dr. Laurence Reilly as Interim Chief Medical Officer of the Company.”
John Friend departed as Chief Medical Officer at Cellectar Biosciences, Inc..
“Dr. Reilly succeeds John Friend, MD, who is stepping down but will stay on through mid-November to finalize the ongoing transition.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.